ライブ
Endpoints News#ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this yearEndpoints NewsLawmakers propose China restrictions; #ASCO26 recap; and moreFierceBiotech‘It looks like this hypothesis will pan out’: Cullinan unveils data building case for autoimmune TCEsEndpoints News#ADA26: Roche incretin shot works in mid-stage trial in type 1 diabetesClinical OMICsBlood-Based Risk Score Could Enable Earlier Lung Cancer PreventionClinical OMICsMicroglial State Shift May Determine Whether Alzheimer’s Disease Pathology Leads to DementiaEndpoints NewsIn Washington, biotech's China hawks are winning the conversationClinical OMICsUniversal Coronavirus Vaccine Could Provide Protection Against Future StrainsEndpoints NewsIndustry seeks more clarity on commissioner's voucher programBioWorldMoney raised by biopharmaBioWorldBiopharma money raised: Jan. 1-June 4, 2026BioWorldBioWorld and Nasdaq stock indices
Agilent 2026年2月14日

The Bull Case For Agilent Technologies (A) Could Change Following New PD-L1 Test Approval And Dividend News - simplywall.st

The Bull Case For Agilent Technologies (A) Could Change Following New PD-L1 Test Approval And Dividend News - simplywall.st

原文
本文は利用できません。元の情報源をご確認ください。